Name: Abbott Laboratories (NYSE:ABT) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Abbott Laboratories, income statement, revenues

US$ in millions

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Established Pharmaceutical Products	5,194)	5,066)	4,912)	4,718)	4,303)
Nutritional Products	8,413)	8,154)	7,459)	8,294)	7,647)
Diagnostic Products	9,341)	9,988)	16,584)	15,644)	10,805)
Medical Devices	18,986)	16,887)	14,687)	14,367)	11,787)
Reportable segments	41,934)	40,095)	43,642)	43,023)	34,542)
Other	16)	14)	11)	52)	66)
Net sales to external customers	41,950)	40,109)	43,653)	43,075)	34,608)

Download chart

Item	Description	The company
Net sales to external customers	Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).	Abbott Laboratories net sales to external customers decreased from 2022 to 2023 but then increased from 2023 to 2024 not reaching 2022 level.